APA (7th ed.) Citation

Thieblemont, C., Row, C., Lamy, T., Aucagne, R., Tani, M., Merli, M., . . . André, M. (2025). 254 | RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY. Hematological oncology, 43, 1. https://doi.org/10.1002/hon.70094_254

Chicago Style (17th ed.) Citation

Thieblemont, C., et al. "254 | RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY." Hematological Oncology 43 (2025): 1. https://doi.org/10.1002/hon.70094_254.

MLA (9th ed.) Citation

Thieblemont, C., et al. "254 | RITUXIMAB AND IBRUTINIB COMBINATION IN UNTREATED SMZL AND NMZL: LONG‐TERM OUTCOME AND THE IMPACT OF EARLY MINIMAL RESIDUAL DISEASE FROM THE IELSG47/MALIBU PHASE II STUDY." Hematological Oncology, vol. 43, 2025, p. 1, https://doi.org/10.1002/hon.70094_254.